Aliskiren and irbesartan significantly prevented atherosclerosis progression and improved plaque stabilization in mice compared to untreated controls (P<0.05 for plaque characteristics).
Does aliskiren or other antihypertensive treatments prevent atherosclerosis progression and stabilize plaques in ApoE(-/-) mice with renovascular hypertension?
Direct renin inhibition with aliskiren mediates atherosclerotic plaque stabilization in a hypertensive mouse model, suggesting specific renin-angiotensin system blockade is superior to beta-blockers or calcium channel blockers for preventing atherosclerosis progression.
p-value: p=<0.05
Hypertension is associated with increased risk of cardiovascular diseases. Antihypertensive treatment, particularly blockade of the renin-angiotensin system, contributes to prevent atherosclerosis-mediated cardiovascular events. Direct comparison of different antihypertensive treatments on atherosclerosis and particularly plaque stabilization is sparse. ApoE(-/-) mice with vulnerable (2-kidney, 1-clip renovascular hypertension model) or stable (1-kidney, 1-clip renovascular hypertension model) atherosclerotic plaques were used. Mice were treated with aliskiren (renin inhibitor), irbesartan (angiotensin-receptor blocker), atenolol (beta-blocker), or amlodipine (calcium channel blocker). Atherosclerosis characteristics were assessed. Hemodynamic and hormonal parameters were measured. Aliskiren and irbesartan significantly prevented atherosclerosis progression in 2-kidney, 1-clip mice. Indeed, compared with untreated animals, plaques showed thinner fibrous cap (P<0.05); smaller lipid core (P<0.05); decreased media degeneration, layering, and macrophage content (P<0.05); and increased smooth muscle cell content (P<0.05). Interestingly, aliskiren significantly increased the smooth muscle cell compared with irbesartan. Despite similar blood pressure lowering, only partial plaque stabilization was attained by atenolol and amlodipine. Amlodipine increased plaque smooth muscle cell content (P<0.05), whereas atenolol decreased plaque inflammation (P<0.05). This divergent effect was also observed in 1-kidney, 1-clip mice. Normalizing blood pressure by irbesartan increased the plasma renin concentration (5932+/-1512 ng/mL per hour) more than normalizing it by aliskiren (16085+/-5628 ng/mL per hour). Specific renin-angiotensin system blockade prevents atherosclerosis progression. First, evidence is provided that direct renin inhibition mediates atherosclerotic plaque stabilization. In contrast, beta-blocker and calcium channel blocker treatment only partially stabilize plaques differently influencing atherogenesis. Angiotensin II decisively mediates plaque vulnerability. The plasma renin concentration measurement by an indirect method did not confirm the excessive increase of plasma renin concentration reported in the literature during aliskiren compared with irbesartan or amlodipine treatment.
Nussberger et al. (Tue,) conducted a other in Atherosclerosis and hypertension (animal model). Aliskiren vs. Irbesartan, atenolol, amlodipine, and untreated control was evaluated on Atherosclerosis progression and plaque stabilization characteristics (p=<0.05). Aliskiren and irbesartan significantly prevented atherosclerosis progression and improved plaque stabilization in mice compared to untreated controls (P<0.05 for plaque characteristics).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: